NCT00088010View on ClinicalTrials.gov

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

9,369

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2009

Study Completion Date

November 30, 2009

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

Arzoxifene

20mg, oral, tablet, once a day for 36 months

DRUG

Placebo

oral, tablet, once a day for 36 months

Trial Locations (1)

60007

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elk Grove

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00088010 - Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer | Biotech Hunter | Biotech Hunter